About Clinigen Group PLC (LON:CLIN)
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company's principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:CLIN
- CUSIP: N/A
- Web: www.clinigengroup.com/
- Market Cap: £1.29 billion
- Outstanding Shares: 115,099,000
- 50 Day Moving Avg: GBX 1,108.08
- 200 Day Moving Avg: GBX 952.65
- 52 Week Range: GBX 695 - GBX 1,175
Sales & Book Value:
- Trailing P/E Ratio: 350.00
- P/E Growth: 0.00
- Annual Revenue: £302.3 million
- Price / Sales: 4.26
- Book Value: GBX 2.16 per share
- Price / Book: 5.19
- EBITDA: £61.3 million
- Net Margins: 0.70%
- Return on Equity: 0.98%
- Return on Assets: 0.53%
- Average Volume: 429,503 shs.
Frequently Asked Questions for Clinigen Group PLC (LON:CLIN)
What is Clinigen Group PLC's stock symbol?
Clinigen Group PLC trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."
How often does Clinigen Group PLC pay dividends? What is the dividend yield for Clinigen Group PLC?
Clinigen Group PLC declared a dividend on Thursday, September 28th. Shareholders of record on Thursday, November 9th will be given a dividend of GBX 3.40 per share on Friday, December 1st. This represents a yield of 0.32%. The ex-dividend date is Thursday, November 9th. This is a positive change from Clinigen Group PLC's previous dividend of $1.60. The official announcement can be seen at this link. View Clinigen Group PLC's Dividend History.
How were Clinigen Group PLC's earnings last quarter?
Clinigen Group PLC (LON:CLIN) announced its earnings results on Thursday, September, 28th. The company reported $41.80 earnings per share for the quarter, beating the Zacks' consensus estimate of $41.20 by $0.60. The business had revenue of $302.30 million for the quarter. Clinigen Group PLC had a net margin of 0.70% and a return on equity of 0.98%. View Clinigen Group PLC's Earnings History.
Where is Clinigen Group PLC's stock going? Where will Clinigen Group PLC's stock price be in 2017?
4 brokerages have issued twelve-month price targets for Clinigen Group PLC's stock. Their forecasts range from GBX 895 to GBX 1,350. On average, they anticipate Clinigen Group PLC's share price to reach GBX 1,078.75 in the next year. View Analyst Ratings for Clinigen Group PLC.
Who are some of Clinigen Group PLC's key competitors?
Some companies that are related to Clinigen Group PLC include Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Prothena Corporation PLC (PRTA), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Array BioPharma (ARRY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), NovoCure Limited (NVCR), Acceleron Pharma (XLRN), Radius Health (RDUS), AnaptysBio (ANAB), Five Prime Therapeutics (FPRX), Acorda Therapeutics (ACOR), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), MyoKardia (MYOK) and Dermira (DERM).
Who are Clinigen Group PLC's key executives?
Clinigen Group PLC's management team includes the folowing people:
- Shaun Edward Chilton, Chief Executive Officer, Director
- Martin James Abell, Chief Financial Officer - Elect, Director
- Peter Vance Allen, Independent Non-Executive Chairman of the Board
- John Bacon, Non-Executive Director
- Peter Lutz George, Non-Executive Director
- John Hartup, Independent Non-Executive Director
- Ian J. Nicholson, Independent Non-Executive Director
How do I buy Clinigen Group PLC stock?
Shares of Clinigen Group PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Clinigen Group PLC's stock price today?
MarketBeat Community Rating for Clinigen Group PLC (LON CLIN)MarketBeat's community ratings are surveys of what our community members think about Clinigen Group PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Clinigen Group PLC stock can currently be purchased for approximately GBX 1,120.
Consensus Ratings for Clinigen Group PLC (LON:CLIN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 3 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.75)|
|Consensus Price Target: ||GBX 1,078.75|Consensus Price Target History for Clinigen Group PLC (LON:CLIN)
Analysts' Ratings History for Clinigen Group PLC (LON:CLIN)
(Data available from 10/17/2015 forward)
|10/10/2017||Peel Hunt||Upgrade||Buy||GBX 1,200 -> GBX 1,350|
|7/18/2017||Numis Securities Ltd||Downgrade||Add||GBX 1,100|
|5/22/2017||Stifel Nicolaus||Reiterated Rating||Buy||GBX 970|
|4/13/2017||N+1 Singer||Reiterated Rating||Buy||GBX 895|
|1/20/2016||Royal Bank Of Canada||Lower Price Target||Outperform||GBX 770 -> GBX 750|
Earnings History for Clinigen Group PLC (LON:CLIN)Earnings History by Quarter for Clinigen Group PLC (LON CLIN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|9/28/2017||Y 2017||GBX 41.20||GBX 41.80||£302.30 million||View||N/A|
Earnings Estimates for Clinigen Group PLC (LON:CLIN)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History by Quarter for Clinigen Group PLC (LON CLIN)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Clinigen Group PLC (LON:CLIN)Insider Trades by Quarter for Clinigen Group PLC (LON:CLIN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/13/2017||Shaun Edward Chilton||Insider||Sell||100,000||GBX 1,150||£1,150,000|
|10/2/2017||John Bacon||Insider||Sell||250,000||GBX 1,093||£2,732,500|
|6/28/2017||John Bacon||Insider||Sell||200,000||GBX 843||£1,686,000|
|6/22/2017||Peter George||former CEO||Sell||500,000||GBX 875||£4,375,000|
|11/11/2016||John Bacon||Insider||Sell||200,000||GBX 717||£1,434,000|
|10/18/2016||Shaun Edward Chilton||Insider||Sell||97,246||GBX 750||£729,345|
|10/7/2015||Edward Chilton,Shaun||Insider||Sell||412,778||GBX 685||£2,827,529.30|
|6/3/2015||John Hartup||Insider||Sell||23,934||GBX 644||£154,134.96|
Headline Trends for Clinigen Group PLC (LON:CLIN)
Latest Headlines for Clinigen Group PLC (LON:CLIN)
Clinigen Group PLC (CLIN) Chart for Tuesday, October, 17, 2017